Venn Life Sciences expands into France with acquisition of DCI

9 Nov 2010

Dublin-based Venn Life Sciences has acquired Paris-based clinical research organisation DCI. DCI offers clinical trial management services for Phase I-IV and contract placement solutions for clinical research projects.

“It is an exciting day for Venn,” said Tony Richardson, Venn’s CEO. “We are constantly seeking to improve what we offer to our sponsors both in geographic reach and scale of services. This addition to our group extends our operations throughout Europe, enhancing an already extensive breadth of expertise in therapeutic indications and clinical trial management services".

The acquisition is a key milestone for Venn in its objective to become a leading international player, offering sponsors increased access to principal investigators and patient pools worldwide. A major focus area for Venn is local on the ground regulatory knowledge especially in Europe which has long been a complex area for drug development organisations.

DCI brings extensive knowledge of the French clinical trial industry. With over 20 years' experience DCI counts some of the world’s leading pharmaceutical and biotech companies among its clients.

“The pace of growth at Venn sees us joining a company at a very exciting time and being part of Venn will enable us to better leverage our expertise offering our local clients access to international sites and personnel with worldwide experience of clinical trial management,” said Frédérique Cabrières, founder of DCI. "Both company’s business ethic is focused on a commitment to excellence and quality and this can only be reinforced by the coming together of the two organisations."

To top